1. Home
  2. MNPR vs TCPC Comparison

MNPR vs TCPC Comparison

Compare MNPR & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$62.74

Market Cap

368.9M

Sector

Health Care

ML Signal

HOLD

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

HOLD

Current Price

$3.76

Market Cap

354.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNPR
TCPC
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
368.9M
354.1M
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
MNPR
TCPC
Price
$62.74
$3.76
Analyst Decision
Strong Buy
Sell
Analyst Count
11
2
Target Price
$107.00
$3.50
AVG Volume (30 Days)
164.9K
610.2K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
18.23%
EPS Growth
54.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.40
$3.43
52 Week High
$105.00
$8.05

Technical Indicators

Market Signals
Indicator
MNPR
TCPC
Relative Strength Index (RSI) 56.98 33.48
Support Level $51.71 $3.43
Resistance Level $67.90 $3.75
Average True Range (ATR) 5.65 0.14
MACD 0.27 -0.07
Stochastic Oscillator 68.24 8.67

Price Performance

Historical Comparison
MNPR
TCPC

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.

Share on Social Networks: